Mu.Ta.Lig - COST ACTION CA15135

Prof. Andrej BOHAC

14 June 2016


General information

Name: Boháč
Surname: Andrej
Cell phone number with international prefix: +421902522144
Country: Slovakia
Affiliation: Comenius University in Bratislava, Slovakia and CEO of Biomagi Ltd.
Gender: M
Year of the PhD title: 1993, Regioselective Acetylations of 1,3-Dicarbonyl Compounds by Ketene and Their Exploitation in Organoiron Chemistry
Personal web page:
Previous COST participation: Yes


List of 10 selected publications within last 5 years

1. M. Vojtičková, J. Dobiaš, G. Hanquet, G. Addová, R. Cetin-Atalay, D.C. Yildirim, A. Boháč, Ynamide Click chemistry in development of triazole VEGFR2 TK modulators, 2015 EJMECH 103 105-122.
2. L. Lintnerová, L. Kováčiková, G. Hanquet, A. Boháč, Selected Methodologies Convenient for the Synthesis of N,5-Diaryloxazole-2-amine Pharmacophore, J. Heterocyclic Chem. 2015 52 425–439.
3. L. Lintnerová, M. García-Caballero, F. Gregáň, M. Melicherčík, A. R. Quesada, J. Dobiaš, J. Lác, M. Sališová, A. Boháč; A development of chimeric VEGFR2 TK inhibitor based on two ligand conformers from PDB: 1Y6A complex – Medicinal chemistry consequences of a TKs analysis EJMECH 72 2014 146-159.
4. M. Murár, G. Addová, A. Boháč; Synthesis of 5-(ethylsulfonyl)-2-methoxyaniline: An important pharmacological fragment of VEGFR2 and other inhibitors, Beilstein J Org Chem 9 2013 173-179.
5. R. Gašparová, P. Koiš, M. Lácová, S. Kováčová, A. Boháč; Synthesis, reactions and antineoplastic activity of 3-(2-oxo-2H-chromen-3-yl)-2-oxo-2H,5H-pyrano[3,2-c]chromene derivatives, Central Euro J of Chem 11 2013 502-513.
6. M. Ilić, J. Ilaš, P. Dunkel, P. Mátyus, A. Boháč, S. Liekens, D. Kikelj, Novel 1,4-benzoxazine and 1,4-benzodioxine inhibitors of angiogenesis, EJMECH 58 2012 160-170.
7. B. Gabajová, D. Valková, A. Boháč, E. Kováčová, R. Moravčík, M. Zeman; hVEGF165 Expression in Escherichia coli Conserves Its Biological Function J Chem ChemEng 6 2012, 738-743.
8. M. Remko, A. Boháč, L. Kováčiková; Molecular structure, pKa, lipophilicity, solubility, absorption, polar surface area, and blood brain barrier penetration of some antiangiogenic agents, Structural Chem 22 2011 635-648.
9. Lacova, M.; Bohac, A.; Biologically active compounds with pyrano[3,2-c]chromen-2(5H)-one skeleton and a method of their preparation Slovakia PATENT 2011 SK 287542 B6 20110104.
10. M. Lácová, R. Gašparová, P. Koiš, A. Boháč, H. M. El-Shaaer; A facile route to phenyl, phenylsulfanyl and phenylselanyl substituted pyrano[3,2-c]chromenes Tetrahedron 66 2010 1410-1419.


Main skills and expertise (up to 5)

1.      Medicinal chemistry
2.      Kinase conformation analysis
3.      Kinase inhibitors development
4.      Hedgehog SMO GPCR modulators development
5.      Organic synthesis, heterocyclic chemistry, compound phy-chem characterization


Main equipment/facilities available in the participants’ lab (up to 5)

1.      all current equipment to perform organic synthesis
2.      computer cluster for structure design
3.      clean biological lab
4.      HPLC, department: HPLC MS, GC MS)
5.      department: NMR 300, 600 MHz, IR, UV



Short personal activity proposal for the COST Action CA15135 (max 1000 characters)

I am 51 year old university teacher and researcher from Slovakia. I studied organic and bioorganic chemistry at Comenius University in Bratislava, Slovakia (1983 – 1987). I finished my PhD study in 1993. Than I was on postdoctoral fellowship (1993-1996) under prof. C. Ganter and D. Seebach at the Federal Institute of Technology (ETH) Zürich, Switzerland where I made a research on Meerwein Sigmatropic Rearrangements of Tricyclic Skeletons and New Chiral Taddol Derivatives Development. Since 2003 I became an associate professor at Comenius University, Slovakia. I am a member of Slovak Chemical society since 1985 and American Chemical Soc. since 2007. I teach Medicinal chemistry, Stereoselective synthesis and Organic chemistry at Comenius University. I have supervised 37 graduated and 8 PhD students. I am author or co-author of 36 papers and patents (Tramal, Allegra, …) with 228 citations. In 2010 I composed a private research company Biomagi, Ltd. Since 2010 I became a Chair of Medicinal Chemistry Division of Slovak Chemical Society and since 2011 I am a Coordinator for Comenius University, Slovakia in Paul Ehrlich European PhD Network in Medicinal Chemistry. My research is focused on cancer drug discovery. We are specialized on development of angiogenic inhibitors and compounds targeting drug resistance in cancer stem cells by structure or fragment based design and Click chemistry methodology. Particularly we are developing (design, synthesis, optimization) tyrosine kinase inhibitors (VEGFR2, Tyro3, Axl, Mer etc.) and SMO GPC-receptor modulators. Our rationale development is based mostly on a structure computer design (target selection and analysis, chemoinformatics, structural data collection and selection, molecular modeling, docking). We are able to predict small organic compounds – target modulators, possessing drug like properties. We have some connections to biological screening for the above kinase and SMO modulators. We have been included in two COST Actions CM0602 (2007-2011): Inhibitors of angiogenesis: design, synthesis and biological exploitation (ANGIOKEM) and CM1106 (2012-2016) Chemical Approaches to Targeting Drug Resistance in Cancer Stem Cells (StemChem). We are willing to cooperate with chemists and biologists by development of novel target modulators: with chemists for synthesis of proposed inhibitors or their more active derivatives (optimization) and with biologists for their screening.


Work Group preference: score from 1 (preferred) to 4 (not preferred)

Work Group of the CA15135 COST Action Score
WG1: Development of new chemical entities 1
WG2: Selection of biological targets and assessment of biological data  
WG3: Development of chemical databases 2
WG4: Development of Computational methods for multiple ligand design and discovery 3